Binh Nguyen Hoa, Anh Pham Ngoc Kieu, Phuong Nguyen Minh
Daitin & Associates, 19 Hoang Dieu, Dist. 4, Ho Chi Minh City, Vietnam.
Master of Law course S1580107, Major in Economic Law, Law Department, University of Economics and Law, Vietnam National University, 6 Quarter, Linh Trung Ward, Thu Duc District, Ho Chi Minh City, Vietnam.
Pharm Pat Anal. 2016 Jul;5(4):261-70. doi: 10.4155/ppa-2016-0008. Epub 2016 Jun 27.
Ratification of the Trans-Pacific Partnership (TPP) will attract a large number of foreign drug companies in the coming years to Vietnam. It is anticipated to bring investment to Vietnam's pharmaceutical industries, lead to increased infrastructure and enable the use of more sophisticated technologies for the discovery, development and manufacture of drugs. However, with respect to pharmaceutical companies, which are producing generic drugs primarily, the availability of biologic will be reduced. Thus, the consequence is, an increase in drug cost resulting in difficulties for patients wishing to procure these drugs. This will be particularly detrimental for developing countries, such as Vietnam and Malaysia.
《跨太平洋伙伴关系协定》(TPP)的批准将在未来几年吸引大量外国制药公司前往越南。预计这将为越南制药行业带来投资,增加基础设施建设,并使在药物研发与生产中能够使用更先进的技术。然而,对于主要生产仿制药的制药公司而言,生物制剂的可获得性将会降低。因此,结果是药品成本增加,这给希望购买这些药品的患者带来困难。这对越南和马来西亚等发展中国家尤为不利。